


文檔簡介
1、Product Data SheetSulindacCat. No.: HY-B0008CAS No.: 38194-50-2分式: CHFOS分量: 356.41作靶點: COX; Autophagy作通路: Immunology/Inflammation; Autophagy儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數據體外實驗 DMSO : 100 mg/mL (280.58 mM; Need ultrasonic)SolventMass1 mg 5 mg 10 mgConcentra
2、tion制備儲備液1 mM 2.8058 mL 14.0288 mL 28.0576 mL5 mM 0.5612 mL 2.8058 mL 5.6115 mL10 mM 0.2806 mL 1.4029 mL 2.8058 mL請根據產品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;旦配成溶液,請分裝保存,避免反復凍融造成的產品失效。儲備液的保存式和期限:-80C, 6 months; -20C, 1 month。-80C 儲存時,請在 6 個內使,-20C 儲存時,請在 1 個內使。體內實驗請根據您的實驗動物和給藥式選擇適當的溶解案。以下溶解案都請先按照 In Vitro 式配制澄清的儲備液
3、,再依次添加助溶劑:為保證實驗結果的可靠性,澄 的儲備液可以根據儲存條件,適當保存;體內實驗的作液,建議您現現配,當天使; 以下溶劑前顯的百分 指該溶劑在您配制終溶液中的體積占;如在配制過程中出現沉淀、析出現象,可以通過加熱和/或超聲的式助溶1. 請依序添加每種溶劑: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (7.01 mM); Clear solution此案可獲得 2.5 mg/mL (7.01 mM,飽和度未知) 的澄清溶液。以 1 mL 作液為例,取 100 L 25.0 mg/mL 的澄 DMSO
4、 儲備液加到 400 L PEG300 中,混合均勻;向上述體系中加50 L Tween-80,混合均勻;然后繼續加 450 L 理鹽定容 1 mL。2. 請依序添加每種溶劑: 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (7.01 mM); Clear solution此案可獲得 2.5 mg/mL (7.01 mM,飽和度未知) 的澄清溶液。Page 1 of 2 www.MedChemE以 1 mL 作液為例,取 100 L 25.0 mg/mL 的澄均勻。DMSO 儲備液加到 900 L 20% 的 SBE-CD 理
5、鹽溶液中,混合BIOLOGICAL ACTIVITY物活性 Sulindac (MK-231)種甾體類抗炎劑,能夠抑制 COX-2 的活性,同時可抑制 COX-2 的過表達。IC & Target COX-2 Autophagy體外研究 Sulindac (MK-231) is a non-steroidal antiinflammatory agent, acts as a COX-2 inhibitor, and inhibits overexpression ofCOX-21. Sulindac (MK-231) (0.1 mM to 0.5 mM) causes limited dea
6、th in both p53 wt and p53 null HCT116 cells, butin combination with vitamin C, it dramatically increases almost 5-fold in cell death in p53 wt HCT116 cells relative tothe vitamin C alone, and such an effect is involving caspase activation and p53 function in these cells, and via ROS-mediated pathway
7、. Sulindac combined with vitamin C significantly increases PUMA levels, but shows no effect onBim, Bcl-2 and Mcl-1 levels2. Sulindac (MK-231) (500 M) in combination with celecoxib blocks transforming growthfactor (TGF)-1-induced epithelial-mesenchymal transition, migration and invasion in A549 cells
8、. The combinationalso suppresses involvement of sirtuin 1 (SIRT1) in transforming growth factor (TGF)-1-induced epithelial-mesenchymal transition (EMT)3.體內研究 Sulindac (MK-231) (0.5 0.1 mg/day) decreases COX, modolates PGE2 levels and prevents tumor formation in theMin mice1.PROTOCOLCell Assay 2 Cell
9、s are treated with Sulindac (MK-231) and/or vitamin C at the indicated doses for 48 h, and cell viability isanalyzed using a trypan blue exclusion assay. For the annexin V staining assay, cells are treated with 0.5 mM Sulindac(MK-231) and/or 0.5 mM vitamin C for 48 h. The cells are then trypsinized,
10、 washed with PBS, stained with propidiumiodide (PI) and FITC-labeled annexin V for 30 min, and analyzed by flow cytometry using a fluorescence-activated cellsorter2.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice1Administration 1 Female C57B
11、L16J-Min/+ (Min) mice at 5 weeks of age are used in the assay. Beginning at 5-6 weeks of age, 10 Min mice are fed a low-fat AIN-76A chow diet modified with 0.001% ethoxyquin and Sulindac (MK-231), 0.5 0.1mg/day (0.05 mg/kcal/day or approximately 160 ppm) in drinking water. As controls, 9 Min mice an
12、d 5 C57BL/6J-+/+non-affected littermates (+/+) are fed AIN-76A diet without Sulindac. Animals are checked daily for signs of distressor anemia. Animals and their food are weighed twice weekly. During the course of the experiment, there is nodifference in body weight or food consumption among the var
13、ious study groups. No toxicity is observed in theMin/Sulindac group. At 110 days of age, all mice are euthanized by CO2 inhalation, and their intestinal tracts areremoved from esophagus to distal rectum, opened, flushed with saline, and examined under 3 magnification toobtain tumor counts. Tumors ar
14、e counted by an individual blinded to the animals genetic status and treatment.Multiple samples of grossly normal, full-thickness bowel are harvested from the mid small intestine and either frozenin liquid nitrogen or fixed in 10% formalin for histological examination. All samples used for the analy
15、ses in this studyare taken from mid small intestine1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Page 2 of 3 www.MedChemEREFERENCES1. Boolbol SK, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of
16、 familial adenomatous polyposis.Cancer Res. 1996 Jun 1;56(11):2556-60.2. Gong EY, et al. Combined treatment with vitamin C and sulindac synergistically induces p53- and ROS-dependent apoptosis in human colon cancer cells.Toxicol Lett. 2016 Sep 6;258:126-133.3. Cha BK, et al. Celecoxib and sulindac inhibit TGF-1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion viadownregulation of sirtuin 1. Oncotarget. 201
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯系上傳者。文件的所有權益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網頁內容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
- 4. 未經權益所有人同意不得將文件中的內容挪作商業或盈利用途。
- 5. 人人文庫網僅提供信息存儲空間,僅對用戶上傳內容的表現方式做保護處理,對用戶上傳分享的文檔內容本身不做任何修改或編輯,并不能對任何下載內容負責。
- 6. 下載文件中如有侵權或不適當內容,請與我們聯系,我們立即糾正。
- 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 工業自動化系統設計優化研究
- 華為應用限制管理辦法
- 協會業余球員管理辦法
- 生產經營單位安全主體責任規定
- 內部職務異動管理辦法
- 微短劇原汁原味傳統文化策略探析
- 物業法律法規培訓感悟
- 安全生產法律法規培訓簡報
- 交通事故撞成植物人
- 安全生產經理崗位職責
- 《初中語文名著演繹舞臺劇》-通過戲劇欣賞名著
- 2024年中智集團招聘筆試參考題庫附帶答案詳解
- 林下種植中藥材的可行性方案
- 東北大學分析化學期末試卷
- 老年健康照護課件
- 2024屆河北省唐山市玉田縣物理高一第二學期期末質量檢測試題含解析
- 第三方醫療消毒供應中心項目可行性研究報告
- 貨架安裝施工方案
- 專利代理人資格考試實務試題及參考答案
- 運用信息技術助力勞動教育創新發展 論文
- GB/T 4074.8-2009繞組線試驗方法第8部分:測定漆包繞組線溫度指數的試驗方法快速法
評論
0/150
提交評論